Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Monday, November 6th. They presently have a $19.50 price target on the stock.
Other research analysts have also recently issued research reports about the company. ValuEngine upgraded Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 2nd. Ifs Securities reissued an “outperform” rating on shares of Rexahn Pharmaceuticals in a research report on Monday, August 7th. Zacks Investment Research raised Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Wednesday, October 4th. Finally, Seaport Global Securities restated a “buy” rating and issued a $13.00 price objective on shares of Rexahn Pharmaceuticals in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Rexahn Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $13.65.
Rexahn Pharmaceuticals (RNN) traded up $0.19 during mid-day trading on Monday, hitting $2.32. The stock had a trading volume of 860,272 shares, compared to its average volume of 712,123. Rexahn Pharmaceuticals has a 1-year low of $0.38 and a 1-year high of $7.10.
TRADEMARK VIOLATION NOTICE: This article was first reported by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://baseballnewssource.com/markets/rexahn-pharmaceuticals-inc-rnn-receives-buy-rating-from-hc-wainwright/1762081.html.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.